Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires

Executive Summary

FDA is announcing a leadership succession plan for the Office of Policy & Planning ahead of the impending retirement of Associate Commissioner William Hubbard

You may also be interested in...

McClellan’s Policy Clout Creates Big Shoes To Fill At FDA

The planned reorganization of FDA following Commissioner Mark McClellan's departure reflects an emphasis on interactions with Capitol Hill and the Administration

FDA Anti-Counterfeit Technology Policy Head Is Ex-CMS Staffer Rudolf

FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD

FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors

FDA Senior Economic Advisor Tomas Philipson, PhD, will work with Commissioner Mark McClellan, MD/PhD, to develop strategic initiatives





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts